N1-Methylpseudouridine: Mechanisms of mRNA Translation Enhancement and Immunogenicity Reduction

Introduction

The field of mRNA therapeutics has rapidly evolved, driven by the need for precise, efficient, and safe gene expression tools. Among the most impactful innovations is the use of chemically modified nucleosides to enhance mRNA stability, translation efficiency, and immune evasion. N1-Methylpseudouridine (N1mΨ) has emerged as the modified nucleoside of choice, outperforming conventional modifications such as 5-methylcytidine and pseudouridine in diverse cellular and in vivo contexts. Research has established N1-Methylpseudouridine’s role in mRNA translation enhancement and its capacity to modulate the innate immune response, making it indispensable for applications in protein expression, cancer research, and neurodegenerative disease models.

Molecular Mechanisms: N1-Methylpseudouridine and mRNA Translation Enhancement

N1-Methylpseudouridine is a synthetic nucleoside analog (C₁₀H₁₄N₂O₆, MW 258.23) that incorporates a methyl group at the N1 position of pseudouridine. When introduced into mRNA transcripts, this modification exerts pleiotropic effects on translation machinery. Mechanistically, N1-Methylpseudouridine suppresses immune activation and eIF2α phosphorylation–dependent inhibition of translation, leading to increased ribosome density and enhanced protein synthesis. This is significant for achieving high protein yields in mammalian cell lines such as A549, BJ, C2C12, HeLa, and primary keratinocytes. Furthermore, N1mΨ reduces cytotoxicity and immunogenicity, particularly when combined with 5-methylcytidine, by diminishing the activation of intracellular innate immune sensors, including TLRs and RIG-I–like receptors.

Unlike many other nucleoside modifications, N1-Methylpseudouridine’s unique structure minimizes recognition by pattern recognition receptors, thereby reducing the innate immune response without compromising translation fidelity. This balance is essential for research applications requiring robust protein expression and minimal inflammatory signaling, such as in cancer research and neurodegenerative disease models.

Translation Regulation via eIF2α Phosphorylation and Immunogenicity Control

The phosphorylation state of eIF2α serves as a central checkpoint in mRNA translation, especially under cellular stress or immune activation. Phosphorylation of eIF2α typically halts translation initiation, limiting protein synthesis and altering cellular fate. N1-Methylpseudouridine modified nucleoside effectively bypasses this translational block by suppressing eIF2α phosphorylation in response to exogenous mRNA, thereby sustaining translation even in environments prone to stress-induced translational repression.

Additionally, immune evasion is critical in both basic and translational research. Modified mRNAs containing N1-Methylpseudouridine demonstrate a marked reduction in interferon and cytokine responses, as compared to unmodified or pseudouridine-containing mRNAs. This property supports the development of next-generation mRNA therapeutics and vaccines, where safety and efficacy are closely tied to the modulation of the innate immune response.

Practical Considerations: Solubility, Handling, and Application Scope

N1-Methylpseudouridine is supplied as a solid and exhibits excellent solubility in water (≥50 mg/mL with ultrasonic assistance), ethanol (≥20 mg/mL), and DMSO (≥20.65 mg/mL), providing flexibility in formulation and experimental design. It should be stored at -20°C, with solutions prepared fresh to maintain stability. Shipping under blue ice (for small molecules) or dry ice (for nucleotides) preserves product integrity. These characteristics make N1mΨ suitable for diverse delivery methods, including lipofection for in vitro and in vivo studies.

In animal models, such as 7-week-old Balb/c mice, intradermal or intramuscular administration of N1-Methylpseudouridine-modified mRNA by lipofection resulted in superior protein expression and lower immunogenicity compared to pseudouridine, underscoring its translational relevance.

N1-Methylpseudouridine in the Context of Mitochondrial and Metabolic Regulation

Recent advances in mitochondrial biology highlight the interplay between metabolic regulation and protein homeostasis. A pivotal study by Wang et al. (Molecular Cell, 2025) demonstrated that the mitochondrial DNAJC co-chaperone TCAIM specifically binds and downregulates the OGDH protein, a key component of the tricarboxylic acid (TCA) cycle. By reducing OGDH activity, TCAIM shifts cellular metabolism and impacts mitochondrial energy production. This study underscores the importance of precise regulation of protein expression and post-translational control mechanisms in metabolic homeostasis.

N1-Methylpseudouridine’s ability to drive high-level, sustained protein expression in mammalian cells provides a powerful tool for dissecting such regulatory networks. For example, researchers can employ N1mΨ-modified mRNA to overexpress or rescue metabolic enzymes (such as OGDH) in cell and animal models, facilitating investigations into the consequences of altered protein turnover, post-translational regulation, and metabolic flux. This is particularly valuable for exploring the effects of chaperone-mediated protein degradation, as highlighted in the TCAIM-OGDH model, and for developing interventions targeting mitochondrial dysfunction in metabolic diseases or cancer.

Applications in Cancer and Neurodegenerative Disease Models

The dual capacity of N1-Methylpseudouridine for mRNA translation enhancement and innate immune response modulation makes it highly attractive for disease modeling and therapeutic research. In cancer research, robust and transient expression of tumor antigens, immune checkpoint proteins, or metabolic regulators is critical for elucidating tumor-immune interactions and testing novel immunotherapies. N1mΨ-modified mRNA enables efficient expression of these proteins with minimal confounding immune activation, improving experimental fidelity.

Similarly, in neurodegenerative disease models, delivery of mRNAs encoding neuroprotective factors, chaperones, or enzymes implicated in neuronal health can be optimized using N1-Methylpseudouridine. The reduction in cytotoxicity and immunogenicity allows for repeated administration and long-term studies without compromising neuronal viability or function, addressing key limitations in preclinical research.

Comparison with Other mRNA Modifications

While several nucleoside analogs have been tested for their ability to enhance mRNA performance, N1-Methylpseudouridine consistently outperforms alternatives such as 5-methylcytidine and pseudouridine. Its superior translation capacity and favorable immune profile are well documented in both in vitro and in vivo systems. When used in combination with other modifications, synergistic effects on translation efficiency and immune suppression can be achieved, further expanding its utility for complex research applications.

Importantly, the mechanistic benefits of N1mΨ extend beyond simple enhancement of protein yield. By supporting translation under phosphorylated eIF2α conditions and limiting innate immune detection, this modification enables studies that would otherwise be confounded by translational repression or inflammatory artifacts.

Guidelines for Researchers: Experimental Design and Best Practices

For optimal results, researchers should consider the following guidelines when employing N1-Methylpseudouridine in mRNA-based experiments:

• Incorporate N1mΨ at full or partial replacement levels for uridine residues during in vitro transcription to maximize translation and minimize immunogenicity.
• Optimize delivery conditions (e.g., lipofection, nanoparticle formulations) to ensure efficient cellular uptake.
• Monitor eIF2α phosphorylation status and innate immune activation markers to confirm the desired modulation of translation and immune responses.
• Prepare fresh solutions and avoid long-term storage of nucleoside stock solutions to preserve chemical integrity.
• Design control experiments using unmodified or alternative nucleoside-modified mRNAs to validate the specific effects of N1-Methylpseudouridine.

Conclusion

N1-Methylpseudouridine stands at the forefront of mRNA modification for protein expression, offering unmatched capabilities in mRNA translation enhancement and immune response modulation. Its mechanistic advantages, including suppression of eIF2α phosphorylation–dependent translation inhibition and reduced immunogenicity, are particularly valuable for advanced applications in cancer research, neurodegenerative disease modeling, and metabolic studies. As outlined in the recent work by Wang et al. (Molecular Cell, 2025), the ability to manipulate protein levels and metabolic pathways underscores the need for robust, precise mRNA delivery systems—an area where N1-Methylpseudouridine excels.

This article extends the discussion beyond the scope of previous summaries, such as N1-Methylpseudouridine: Advancing mRNA Translation and Pr..., by providing a deeper mechanistic analysis and highlighting new opportunities for integrating mRNA modifications into metabolic and disease research. By connecting the molecular features of N1mΨ to emerging trends in mitochondrial regulation and protein homeostasis, this review offers a comprehensive resource for researchers seeking to leverage this technology in the context of cutting-edge biomedical investigation.